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Background: Gastrointestinal bleeding (GIB) is a common and often serious complication after stroke. Although
several risk factors for post-stroke GIB have been identified, no reliable or validated scoring system is currently available
to predict GIB after acute stroke in routine clinical practice or clinical trials. In the present study, we aimed to develop
and validate a risk model (acute ischemic stroke associated gastrointestinal bleeding score, the AIS-GIB score) to predict
in-hospital GIB after acute ischemic stroke.
Methods: The AIS-GIB score was developed from data in the China National Stroke Registry (CNSR). Eligible patients in
the CNSR were randomly divided into derivation (60%) and internal validation (40%) cohorts. External validation was
performed using data from the prospective Chinese Intracranial Atherosclerosis Study (CICAS). Independent predictors
of in-hospital GIB were obtained using multivariable logistic regression in the derivation cohort, and β-coefficients were
used to generate point scoring system for the AIS-GIB. The area under the receiver operating characteristic curve (AUROC)
and the Hosmer-Lemeshow goodness-of-fit test were used to assess model discrimination and calibration, respectively.
Results: A total of 8,820, 5,882, and 2,938 patients were enrolled in the derivation, internal validation and external
validation cohorts. The overall in-hospital GIB after AIS was 2.6%, 2.3%, and 1.5% in the derivation, internal, and external
validation cohort, respectively. An 18-point AIS-GIB score was developed from the set of independent predictors of GIB
including age, gender, history of hypertension, hepatic cirrhosis, peptic ulcer or previous GIB, pre-stroke dependence,
admission National Institutes of Health stroke scale score, Glasgow Coma Scale score and stroke subtype (Oxfordshire).
The AIS-GIB score showed good discrimination in the derivation (0.79; 95% CI, 0.764-0.825), internal (0.78; 95% CI, 0.74-0.82)
and external (0.76; 95% CI, 0.71-0.82) validation cohorts. The AIS-GIB score was well calibrated in the derivation (P = 0.42),
internal (P = 0.45) and external (P = 0.86) validation cohorts.
Conclusion: The AIS-GIB score is a valid clinical grading scale to predict in-hospital GIB after AIS. Further studies on the
effect of the AIS-GIB score on reducing GIB and improving outcome after AIS are warranted.Background
Gastrointestinal bleeding (GIB) is a serious complication
after acute stroke with an estimated incidence of 1%-5%
[1-8]. Several risk factors for post-stroke GIB have been
identified [2,6-9], such as advanced age, medical history
of peptic ulcer or previous GIB, admission stroke severity,
and impaired level of consciousness. However, no reliable
or validated scoring system is currently available to predict
GIB after acute stroke in routine clinical practice or
clinical trials. An effective risk stratification model would* Correspondence: yongjunwang1962@gmail.com
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medical resources, and contrapuntally implement
prophylactic strategies, such as the use of histamine H2
receptor antagonists (H2RAs) or proton pump inhibitors
(PPIs) [10-18]. A predictive scoring system would also be
useful in clinical trials and health outcomes research by
providing an objective method to risk-adjust when
determining endpoints. In the present study, we aimed to
develop and validate a risk score (Acute Ischemic Stroke
associated Gastrointestinal Bleeding Score, AIS-GIB
score) for predicting GIB during acute hospitalization after
acute ischemic stroke (AIS).his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Derivation, internal and external validation cohorts
The derivation and internal validation cohorts were
obtained from the largest stroke registry in China, the China
National Stroke Registry (CNSR), which is a nationwide,
multicenter, prospective registry of consecutive patients with
acute cerebrovascular events [19]. Briefly, hospitals in China
are classified into 3 grades: I (community hospitals); II
(hospitals that serve several communities); or III (central
hospitals for a certain district or city). The CNSR includes
132 hospitals including 100 grade III and 32 grade II
hospitals covering 27 provinces and 4 municipalities
across China. These sites were carefully selected from
a total of 242 urban and rural hospitals by the CNSR
steering committee based on their research capability and
commitment to the registry. Trained research coordinators
at each hospital review medical records daily to screen,
consent and enroll consecutive patients. To be eligible
for this study, subjects had to meet the following
criteria: (1) age 18 years or older; (2) hospitalized
with a primary diagnosis of AIS according to the
World Health Organization (WHO) criteria [20]; (3)
stroke confirmed by head computerized tomography
(CT) or brain magnetic resonance imaging (MRI); (4)
direct admission to hospital from a physician’s clinic
or emergency department. Eligible patients from the
CNSR were randomly divided into derivation (60%)
and validation (40%) cohorts.
The external validation cohort was derived from the
Chinese Intracranial Atherosclerosis Study (CICAS) [21],
which was a hospital-based, multicenter, prospective
study aiming at investigating the incidence, risk factors
and impact of intracranial atherosclerosis among patients
with AIS. Inclusion criteria of the CICAS were: (1)
age 18 to 80 years; (2) symptom onset within 7 days;
(3) hospitalized with a primary diagnosis of AIS or
transient ischemic attack (TIA). Exclusion criteria of
the CICAS were: (1) pre-admission modified Rankin
Scale (mRS) score ≥ 3; (2) inability to undergo MRI
for cerebral vascular imaging. For the present study,
patients diagnosed with TIA were excluded.
Informed consent was obtained for all patients enrolled
in the CNSR and CICAS. The scientific use of data
registered in the CNSR and CICAS was approved by
the central institutional review board at Beijing Tiantan
Hospital and local ethical committees at each participating
hospital in the CNSR and CICAS (Additional file 1:
Appendix A and B).
Data collection and variables definitions
In these registries, a standardized case report form (CRF)
is used for data collection. Relevant data is extracted from
medical records by trained research coordinators. Data
from each CRF is manually checked for completeness,correct coding, and proper application of diagnostic
algorithms by research specialists from an independent
contract research organization.
In the present study, the following candidate variables
were analyzed: (1) demographics (age and gender); (2)
stroke risk factors: hypertension (history of hypertension
or anti-hypertensive medication use), diabetes mellitus
(history of diabetes mellitus or anti-diabetic medication
use), dyslipidemia (history of dyslipidemia or lipid-lowering
medication use), atrial fibrillation (history of atrial fibrilla-
tion or documentation of atrial fibrillation on admission),
coronary heart disease, peripheral artery disease, history of
stroke/TIA, current smoking, and excess alcohol consump-
tion (≥2 standard alcohol beverages per day); (3) preexisting
comorbidities: congestive heart failure, valvular heart
disease, chronic obstructive pulmonary disease (COPD),
hepatic cirrhosis, peptic ulcer, previous GIB, renal failure,
arthritis, Alzheimer’s disease/dementia, and cancer; (4)
pre-stroke functional status based on the mRS score
derived from the medical record, categorized as mRS < 3
or ≥ 3; (5) pre-admission anticoagulant (warfarin) use or
anti-platelet medication use (aspirin, clopidogrel, or
extended release dipyridamole combined with aspirin); (6)
admission systolic and diastolic blood pressure (mm Hg);
(7) admission stroke severity based on the National
Institutes of Health Stroke Scale score (NIHSS) score
and the Glasgow Coma Scale (GCS) score; (8) stroke
subtype according to the Oxfordshire Community Stroke
Project (OCSP) criteria [22] where AIS is classified into
partial anterior circulation infarct (PACI), total anterior
circulation infarct (TACI), lacunar infarction (LACI), and
posterior circulation infarct (POCI); (9) intravenous tissue
plasminogen activator (t-PA) thrombolysis within 3 h after
onset; (10) antiplatelet or antithrombotic therapy on
admission; (11) length of hospital stay (days).
GIB was defined according to Davenport et al. [2] as
any episode of fresh blood or coffee ground emesis,
hematemesis, melena, or hematochezia occurring during
index hospitalization. GIB after AIS were diagnosed by
treating physicians (with or without blood transfusion)
and prospectively registered by trained research coordi-
nators. Only GIB developed during hospitalization was
documented and GIB occurred before admission was
not considered. Data on the development of GIB after
AIS were manually checked for completeness, correct
coding, and proper application of diagnostic algorithm
by a research specialist from an independent contract
research organization.
Statistical analysis
Model building was performed exclusively in the deriv-
ation cohort. In univariate analysis, Chi-square and
Mann-Whitney tests were used as appropriate. Multivari-
able logistic regression was used to determine independent
Ji et al. BMC Gastroenterology 2014, 14:130 Page 3 of 9
http://www.biomedcentral.com/1471-230X/14/130predictors for GIB after AIS in the derivation cohort.
Candidate variables were those with biologically plausible
link to GIB on the basis of prior publication and those
associated with GIB in univariate analysis (P < 0.1). On
multivariable analysis, backward stepwise method was
used. To test for collinearity between the covariates of the
final multivariable model, the tolerance and variance
inflation factor (VIF) of each covariate was calculated.
The β-coefficients from the final model were used to
generate a point scoring system of the AIS-GIB score,
as in previous studies [23]. The resulting risk score
was then validated by assessing model discrimination
and calibration in the internal and external validation
cohort [24]. Discrimination, i.e. the degree to which
the prognostic score enables the discrimination between
patients with and without GIB after AIS, was assessed
by calculating the area under the receiver operating
characteristic curve (AUROC). An AUROC of 1.0
indicates perfect prediction, whereas a C statistic of 0.5
indicates no better than random prediction. Calibration,
i.e. the agreement between predicted and observed risk of
GIB, was assessed by performing the Hosmer-Lemeshow
goodness-of-fit test and was graphically depicted in the
plot of observed versus predicted GIB risk according to 10
deciles of predicted risk.
All tests were 2-tailed and statistical significance was set
at a value of p < 0.05. Statistical analysis was performed
using SAS 9.1 (SAS Institute, Cary, NC) and SPSS 17.0
(SPSS Inc., Chicago, IL).
Results
Patient characteristics
Patient characteristics in the derivation, internal and
external validation cohorts were shown in Table 1. From
September 2007 to August 2008, a total of 14,702
patients with AIS were enrolled in the CNSR. The
median age was 66 years (IQR 58-75) and 62% were
male. The median length of hospital stay (LOS) was
14 days (IQR, 10-21). The median admission NIHSS
score was 5 (IQR, 2-9). A total of 362 (2.5%) patients had
GIB during hospitalization, of whom 39 (0.3%) required
blood transfusion. The derivation cohort (n = 8,820) and
internal validation cohort (n = 5,882) were matched with
respect to baseline characteristics and rates of in-hospital
GIB (Table 1).
From October 2007 to June 2009, a total of 3,580
patients were registered in 22 participating hospitals in
the CICAS network. Of these, we excluded 329 patients
with TIA (9.1%) and an additional 313 patients (8.7%)
who were missing data for one or more covariates used
in the AIS-GIB score. The final external validation
cohort comprised 2,938 patients with AIS (Table 1). The
median LOS was 14 days (IQR, 11-18). The median
admission NIHSS score was 4 (IQR, 2-8). A total of 44(1.5%) patients had GIB during hospitalization, of whom 7
(0.2%) required blood transfusion.
Predictors of GIB and derivation of the AIS-GIB score
The univariate analysis for potential predictors for GIB
after AIS in the derivation cohort is shown in Additional
file 1: Table S1. The results of the multivariate analysis,
including β-coefficients for each independent predictor,
are shown in Table 2. The tolerance of covariates in the
final multivariable model ranged between 0.68 and 0.99;
the mean VIF was 1.28 (range: 1.01-1.75).
The β-coefficients from the multivariable regression
model were used to generate scoring system of the AIS-GIB
score (Table 3). To derive an integer value for each
predictor, the β-coefficient of patients younger than
60 years was used as reference and the value was rounded
to the closest integer. When we used β-coefficient of
different variables in the multivariable model as reference,
such as female gender, patients without medical history of
hypertension, patients with admission NIHSS score ≤4, or
patients of lacunar infarction, although the scoring system
was different, the discrimination of the final model was
similar (data not shown). The probability of GIB can be
estimated for an individual patient by summing points
assigned to each predictor to create a total point score
that ranges from 0 to 18. The median AIS-GIB score was
3 (IQR: 2-5; range: 0-15) in the derivation cohort.
Internal validation of the AIS-GIB score
Figure 1 shows the proportion of GIB after AIS according
to the AIS-GIB score. The potential risk of in-hospital
GIB increased steadily with higher AIS-GIB score. The
discrimination of the AIS-GIB score (AUROC) with
regard to any GIB in the derivation and internal validation
cohort was 0.794 (95% C.I. 0.764-0.825) and 0.780 (95% C.I.
0.740-0.820), respectively. The discrimination of the
AIS-GIB score for GIB requiring blood transfusion in the
derivation and internal validation cohort was 0.768
(95% C.I. 0.705-0.872) and 0.771 (95% C.I. 0.712-0.923),
respectively. The Hosmer-Lemeshow test was not signifi-
cant (p = 0.45), and the predicted and observed risk of
GIB were in close agreement according to 10 deciles
of predicted risk in the internal validation cohort (r = 0.96,
P < 0.001) (Additional file 1: Figure S1).
External validation of AIS-GIB score
The AIS-GIB score showed good discrimination for
any GIB (AUROC 0.755, 95% C.I. 0.710-0.818) and
GIB requiring blood transfusion (AUROC 0.738, 95%
C.I. 0.701-0.833) in the external validation cohort. The
AIS-GIB score appeared well calibrated in the external
validation cohort since the Hosmer-Lemeshow test result
was not significant (p = 0.86). The plots of observed versus
predicted risk of GIB showed a high correlation between
Table 1 Patient characteristics
Derivation cohort Internal validation cohort P1 value* External validation cohort P2 value*
(n = 8,820) (n = 5,882) (n = 2,938)
Demographics
Age, y, median (IQR) 66 (56-74) 66 (57-75) 0.11 64 (55-72) <0.001
Gender (male), n (%) 5430 (61.6) 3675 (62.5) 0.27 1927 (65.5) <0.001
Vascular risk factor, n (%)
Hypertension 5601 (63.5) 3683 (62.6) 0.27 1987 (67.6) <0.001
Diabetes mellitus 1834 (20.8) 1287 (21.9) 0.11 720 (24.5) <0.001
Dyslipidemia 947 (10.7) 637 (10.8) 0.86 386 (13.1) <0.001
Atrial fibrillation 643 (7.3) 415 (7.1) 0.60 175 (6.0) 0.01
Coronary artery disease 1222 (13.9) 811 (13.8) 0.91 285 (9.7) <0.001
Peripheral artery disease 64 (0.7) 29 (0.5) 0.08 26 (0.9) 0.39
History of stroke/TIA 2795 (31.7) 1822 (31.0) 0.36 809 (27.5) <0.001
Smoking 3510 (39.8) 2326 (39.5) 0.70 1022 (34.8) <0.001
Heavy alcohol consumption 1346 (15.3) 921 (15.7) 0.55 372 (12.7) <0.001
Others coexistent condition, n (%)
Congestive heart failure 169 (1.9) 121 (2.1) 0.55 24 (0.8) <0.001
Valvular heart disease 213 (2.4) 139 (2.4) 0.83 40 (1.4) 0.001
COPD 98 (1.1) 64 (1.1) 0.88 12 (0.4) 0.001
Hepatic cirrhosis 29 (0.3) 21 (0.4) 0.78 7 (0.2) 0.44
Peptic ulcer or previous GIB 283 (3.2) 195 (3.3) 0.72 76 (2.6) 0.09
Renal failure 7 (0.1) 4 (0.1) 0.80 3 (0.1) 0.71
Arthritis 266 (3.0) 176 (3.0) 0.27 45 (1.5) <0.001
Dementia 113 (1.3) 82 (1.4) 0.57 18 (0.6) 0.003
Cancer 150 (1.7) 109 (1.9) 0.51 54 (1.8) 0.62
Pre-stroke dependence (mRS≥3), n (%) 809 (9.2) 535 (9.1) 0.87 0 (0.0) <0.001
Pre-admission antiplatelet therapy, n (%) 1449 (16.4) 932 (15.8) 0.35 357 (12.2) <0.001
Pre-admission anticoagulation therapy, n (%) 210 (2.4) 122 (2.1) 0.22 26 (0.9) <0.001
Admission NIHSS score, median (IQR) 5 (2-9) 5 (2-9) 0.68 4 (2-8) 0.02
Admission GCS score, median (IQR) 15 (14-15) 15 (14-15) 0.36 15 (15-15) 0.18
Admission SBP (mmHg), median (IQR) 150 (134-163) 150 (135-162) 0.88 150 (135-167) 0.22
Admission DBP (mmHg), median (IQR) 89 (80-95) 89 (80-95) 0.98 90 (80-98) 0.11
OCSP subtype, n (%) 0.22 <0.001
Partial anterior circulation infarct (PACI) 4834 (54.8) 3327 (56.6) 1829 (62.3)
Total anterior circulation infarct (TACI) 811 (9.2) 519 (8.8) 176 (6.0)
Lacunar infarction (LACI) 1667 (18.9) 1074 (18.3) 246 (8.4)
Posterior circulation infarct (POCI) 1508 (17.1) 962 (18.4) 687 (23.4)
Intravenous t-PA within 3 h after onset, n (%) 108 (1.2) 73 (1.2) 0.93 137 (4.6) <0.001
Antithrombotic therapy on admission, n (%) 7371 (83.6) 4950 (84.2) 0.35 2550 (86.8) <0.001
Anticoagulation therapy on admission, n (%) 210 (2.4) 122 (2.1) 0.24 159 (5.4) <0.001
Length of hospital stay (days), median (IQR) 14 (10-20) 14 (10-20) 0.96 14 (11-18) 0.15
In-hospital GIB, n (%) 227 (2.6) 135 (2.3) 0.29 44 (1.5) 0.001
*P1 denotes the P value comparing the derivation and internal validation cohorts; P2 denotes the P value comparing the derivation and external
validation cohorts.
Abbreviations: IQR interquartile range, COPD chronic obstructive pulmonary disease, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale
score, GCS Glasgow Coma Scale, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, OCSP Oxfordshire Community Stroke Project, t-PA tissue
plasminogen activator.
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Table 2 Multivariable predictors of GIB after AIS from the derivation cohort (n = 8,820)
Variables β-coefficients adjusted O.R.* 95% C.I. P value
Model intercept -6.529
Age (years) 0.009 1.01 1.00-1.02 0.01
Gender (male) 0.370 1.45 1.13-1.85 0.004
Hypertension 0.345 1.41 1.10-1.82 0.008
Hepatic cirrhosis 1.299 3.66 1.17-11.5 <0.001
Peptic ulcer or previous GIB 1.226 3.41 2.28-5.10 <0.001
Pre-stroke dependence (mRS≥3) 0.717 2.05 1.54-2.72 <0.001
Admission NIHSS (per 1 point increase) 0.063 1.07 1.04-1.09 <0.001
Admission GCS (per 1 point decrease) 0.057 1.06 1.01-1.11 0.01
OCSP subtype
Lacunar infarction (LACI) … 1.00 … …
Partial anterior circulation infarct (PACI) 0.169 1.18 0.80-1.75 0.39
Total anterior circulation infarct (TACI) 0.457 1.58 1.01-2.49 0.02
Posterior circulation infarct (POCI) 0.804 2.24 1.47-3.40 <0.001
*Multivariable logistic regression adjusted for age, gender, stroke risk factors, comorbidities, pre-stroke dependence, pre-admission antiplatelet therapy,
pre-admission anticoagulation therapy, admission blood pressure, NIHSS score, GCS score, OCSP subtypes, intravenous t-PA, antithrombotic therapies within 48 h
after admission, and length of hospital stay.
Abbreviation: GIB gastrointestinal bleeding, AIS acute ischemic stroke, OR odds ratio, C.I. confidence interval, mRS modified Rankin Scale, NIHSS National Institutes
of Health Stroke Scale score, GCS Glasgow Coma Scale, OCSP Oxfordshire Community Stroke Project, t-PA tissue plasminogen activator.
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predicted risk in the external validation cohort (r = 0.91,
P < 0.001) (Additional file 1: Figure S1).
Sensitivity analysis
We performed pre-specified subgroup analyses by age,
gender, and LOS. Similar good discrimination of the
AIS-GIB score was seen in these subgroups (AUROC
ranges 0.713-0.816, Table 4).
Discussion
In the present study, we derived and validated a clinical risk
score that can be applied at the bedside, upon patient
admission, to predict in-hospital GIB after AIS. Age,
gender, certain pre-existing conditions (hypertension,
hepatic cirrhosis, peptic ulcer disease, previous GIB),
pre-stroke dependence, admission NIHSS score, GCS
score, and OCSP subtype proved to be independent
predictors for in-hospital GIB. These variables were
used to develop the AIS-GIB score, which showed
good discrimination and calibration in large derivation
(n = 8,820), internal (n = 5,882) and external (n = 2,938)
validation cohorts. In sensitive analysis, the AIS-GIB
demonstrated to be valid and significant for patients with
different age, gender, and length of hospital stay.
To preserve the clinical utility of the risk model for
decision-making during acute hospitalization, we used
only patient characteristics available at presentation or
shortly after admission. This model therefore predicts
the expected in-hospital GIB at presentation, and assuch, the predictions could be helpful for identifying
vulnerable patients, allocating relevant medical resources,
implementing contrapuntal prophylactic strategies, such
as the use of histamine H2 receptor antagonists (H2RAs)
or proton pump inhibitors (PPIs) during subsequent
hospitalization.
Several risk factors have been identified for the develop-
ment GIB after acute stroke. Consistent with prior studies,
we confirmed that advanced age [2,8,9], history of peptic
ulcer or previous GIB [6,7,25], history of hypertension
[4,26], pre-stroke dependence [2], admission stroke severity
[4,6,7], impaired consciousness (measured with GCS score)
[2,5,8], and middle cerebral artery territory ischemia
[2,9] were significantly associated with GIB after AIS.
The association between gender and GIB after acute
vascular events has been controversial [25,27]. In accord-
ance with George et al. [27], we showed that male gender
was associated with the increased risk of GIB after AIS in
our Chinese population. Additionally, we identified hep-
atic cirrhosis and posterior circulation stroke (POCI) as
risk factors for developing GIB after AIS. The association
between hepatic cirrhosis and increased risk of GIB after
AIS might be mediated by esophagogastric varices second-
ary to portal hypertension or coagulopathy secondary to
hepatic dysfunction. The pathophysiological mechanism
underlying the association between posterior circulation
ischemia and GIB is not clear. Prior studies indicated that
stress ulcer may develop from what is believed to be vagal
hyperactivity, which would result in increased gastric acid
and pepsin secretion and damage of gastrointestinal
Table 3 The point scoring system of the AIS-GIB score
Items Score Point total Estimate of
risk (%)*
Age group 0 0.3
≤ 59 0 1 0.4
60-69 1 2 0.6
70-79 1 3 1.0
≥80 2 4 1.5
Gender 5 2.4
Female 0 6 3.7
Male 1 7 5.7
Medical history 8 8.7
Hypertension 1 9 13.0
Hepatic cirrhosis 3 10 19.0
Peptic ulcer or previous GIB 3 11 26.8
Pre-stroke disability (mRS≥ 3) 2 12 36.5
Admission NIHSS score 13 47.4
0-4 0 14 58.6
5-9 1 15 68.9
10-14 2 16 77.7
≥15 3 17 84.5
Admission GCS score 18 89.5
15 0
13-14 0
9-12 1
3-8 1
OCSP subtype
Lacunar infarction (LACI) 0
Partial anterior circulation
infarct (PACI)
0
Total anterior circulation infarct (TACI) 1
Posterior circulation infarct (POCI) 2
*The total point score gives the predicted risk of GIB after AIS according to the
following
Equation: Risk of GIB after AIS = 1/(1 + EXP [5.953 ‐ 0.45(Total AIS ‐GIB score)]).
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system after AIS tends to induce excessive catecholamine
discharge, and the following vasoconstriction may result
in splanchnic hypoperfusion and mucosal ischemia [29].
The association between posterior circulation ischemia
and GIB might be attributed to the interruption of the
autonomic nervous system pathway descending from the
hypothalamus via the mesencephalon, pons, and medulla
to the spinal cord. We found no association between
intravenous t-PA therapy and GIB in our study, although
the number of patients receiving IV t-PA in the CNSR
was relatively small.
For a clinical grading scale to become widely used, it
must be reliable, accurate, and practical. First, for reliability,the AIS-GIB score was developed based on a large stroke
registry which included consecutive AIS patients; being a
registry and not a clinical trial the data was more reflective
of real-world clinical practice. Second, for accuracy, the
AIS-GIB score showed good discrimination and calibration,
and the results were verified in independent derivation,
internal and external validation cohorts. Additionally, by
sensitivity analysis, the AIS-GIB score was effective for
patients with different age, gender, and LOS. Third, for
convenience, the AIS-GIB score consists of factors that are
readily available at hospital presentation or shortly after
admission. With the scoring system showing estimated
risk of in-hospital GIB after AIS for each AIS-GIB score
(Table 3), clinicians can quantitatively predict the po-
tential risk at the bedside without doing sophisticated
calculation.
Prior studies have demonstrated that GIB is an important
cause of morbidity and mortality in patients with acute
vascular events [6,27]. In this study, one clinical question
not answered is the potential effect of the AIS-GIB score
on stroke outcomes. The prophylactic use of H2RAs, PPIs,
or sucralfate is all effective in reducing GIB in critically ill
patients [16-18]; however, optimum GIB prevention
strategies are still unclear for patients with AIS. The
AIS-GIB score could be used to identify patients at
particularly high risk and then implement more aggressive
monitoring (e.g. daily stool guaic testing) or more aggressive
prophylaxis (e.g. PPI plus sucralfate).
Our study has limitations. First, given our emphasis on
early prediction, we did not assess the impact of in-hospital
procedures, complications, and medications (such as anti-
platelets, anticoagulants, glucocorticoids, selective serotonin
reuptake inhibitors [30]), which may influence the risk of
GIB. Second, since we only have information on new-onset
GIB during hospitalization without documentation of the
exact date, it remains unclear whether patients with a
longer length of stay are more likely to develop GIB or if
diagnosis of GIB leads to a longer hospitalization. Third,
the generalizability of our study may be limited since the
datasets comprised adults with ischemic stroke admitted
to hospitals, and we excluded outpatients and those with
TIA and hemorrhagic stroke. Fourth, the source of GIB
and the clinical severity of GIB were not determined. Fifth,
the information on pre-existing comorbidities was based
on patients self-report and verified by chart review. Even
though, we cannot sure for collecting all information on
pre-existing comorbidities, especially a history of GIB.
Finally, the AIS-GIB score needed to be further validated
in different populations.
Conclusion
We found that the AIS-GIB score is a valid clinical
grading scale to predict the risk of in-hospital GIB
after AIS. Further studies on the effect of the AIS-GIB
Figure 1 The figure showed the proportion of in-hospital GIB after AIS according to the AIS-GIB score in the derivation (blue bar),
internal (red bar) and external (yellow bar) validation cohort. The risk of in-hospital GIB after AIS increased steadily with higher AIS-GIB score.
Meanwhile, the predicted (green dot line) and observed risk of in-hospital GIB after AIS were in close agreement in the derivation, internal and
external validation cohort.
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are warranted.
Key messages
1. Age, gender, certain pre-existing conditions
(hypertension, hepatic cirrhosis, peptic ulcer
disease, previous GIB), pre-stroke dependence,
admission NIHSS score, GCS score, and OCSP
subtype proved to be independent predictors forTable 4 Sensitivity analysis of the AIS-GIB in the derivation and
Derivation cohort Inter
(n = 8,820)
AUROC 95% C.I. AUROC
Overall cohort 0.794 0.764-0.825 0.780
Subgroups
Age
≤60 0.800 0.747-0.854 0.778
≥61 0.777 0.738-0.815 0.771
Gender
Male 0.797 0.757-0.837 0.795
Female 0.795 0.749-0.841 0.748
Length of hospital stay
<7 days 0.786 0.730-0.841 0.792
7-14 days 0.814 0.739-0.890 0.787
>14 days 0.770 0.728-0.812 0.756
Abbreviations: AUROC area under the receiver operating characteristic curve, C.I. confidin-hospital GIB,based on which an 18-point
GIB-AIS was developed.
2. The GIB-AIS showed good discrimination and
calibration in large derivation, internal and external
validation cohorts.
3. By sensitive analysis, the AIS-GIB demonstrated to
be valid and significant for patients with different
age, gender, and length of hospital stay.
4. Further validation of the GIB-AIS in different
populations is needed.two validation cohorts
nal validation cohort External validation cohort
(n = 5,882) (n = 2,938)
95% C.I. AUROC 95% C.I.
0.740-0.820 0.755 0.710-0.818
0.707-0.848 0.816 0.734-0.898
0.720-0.823 0.737 0.698-0.789
0.748-0.842 0.756 0.701-0.829
0.702-0.819 0.740 0.698-0.845
0.708-0.876 0.713 0.639-0.786
0.715-0.880 0.731 0.679-0.843
0.702-0.809 0.725 0.699-0.856
ence interval.
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Additional file 1: Table S1. Univariate analysis: predictors of GIB after
AIS in the derivation cohort (n = 8,820). Showed univariate predictor of
GIB after AIS in the derivation cohort. Figure S1. Plot of observed versus
predicted risk of in-hospital GIB after AIS in the derivation, internal and
external validation cohorts. Showed plot of observed versus predicted risk
of GIB with 95% confidence intervals in the derivation and validation
cohorts according to 10 deciles of predicted risk. Overall, there was a very
high correlation between observed and predicted risk in the derivation
cohort (A) (n = 8,820; r = 0.99, P < 0.001), internal validation cohort
(B) (n = 5,882; r = 0.96, P < 0.001) and external validation cohort (C)
(n = 2,938, r = 0.91, P < 0.001), which indicated excellent calibration.
Appendix A. The CNSR and CICAS investigators. Appendix B.
Institutional review board within the CNSR and CICAS network.
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